Generate Biomedicines, Inc.

NASDAQ:GENB

Asset Management

Financial Services
$10.38 +0.91%

+$0.13 today

Market cap
$1.34B
Beta
0.19
P/E (TTM)
-3.5
EPS (TTM)
-$4.06
52W Low $11.00High $16.75

Volume 1.05M

Average 0.55M

Returns on capital

Generate Biomedicines, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

33.0%

avg 36.5%

ROIC

-89.4%

avg -66.7%

ROA

-61.5%

avg -47.5%

Analysis

ROE is currently the strongest return metric at 33.0% versus its period average of 36.5%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Michael T. Nally

CEO & DirectorUSD 1.08M50——

Jason E. Silvers

President & CFOUSD 772.9K54——

Gevorg Grigoryan

Co-Founder & CTOUSD 738.02K45——

Noubar Afeyan

Co-founder & Independent Chair of the Board—63——

Sahm Nasseri

Senior Vice President of Business Development & Strategy—41——

Beth Grous

Chief People Officer—58——

Molly Gibson

Co-Founder————

Aarif Khakoo

Chief Scientific Officer—55——

Daria Hazuda

Senior Vice President of Discovery Strategy————

Sean W. Martin

Secretary, Chief Legal Officer & General Counsel—63——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

2

$200,735.39

Net Transaction Value

−$200,735.39

Net selling

Most Active

ARNOLD FRANCES

2 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 29, 26

ARNOLD FRANCES

Direct

Sell$184.7K
Sep 1, 26

ARNOLD FRANCES

Direct

Sell$16K

Summary

Insiders reported 0 buys worth $0.00 and 2 sells worth $200,735.39 over the last 12 months. That adds up to net selling of $200,735.39. ARNOLD FRANCES was the most active insider with 2 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
+38.6% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Forward estimates point to Revenue at +38.6% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does Generate Biomedicines, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about GENB's management, answered from reported figures.

Who manages GENB?

Generate Biomedicines, Inc. (GENB) lists 10 active executives. The top listed executive is Gevorg Grigoryan, Co-Founder & CTO.

Are GENB insiders buying or selling?

Recent insider activity shows net selling of $200,735.39.